Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
1.020
-0.050 (-4.67%)
At close: Sep 5, 2025, 4:00 PM
1.000
-0.020 (-1.95%)
After-hours: Sep 5, 2025, 7:45 PM EDT
Polyrizon Employees
As of December 31, 2024, Polyrizon had 6 total employees, including 2 full-time and 4 part-time employees.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$267,500
Market Cap
11.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLRZ News
- 23 days ago - Polyrizon Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 6 weeks ago - Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - GlobeNewsWire
- 7 weeks ago - Polyrizon Retains Nasdaq Listing Following Hearings Panel - GlobeNewsWire
- 3 months ago - Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics - GlobeNewsWire
- 3 months ago - Polyrizon Announces Receipt of Nasdaq Delisting Notice - GlobeNewsWire
- 3 months ago - Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform - GlobeNewsWire
- 4 months ago - Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment - GlobeNewsWire
- 4 months ago - Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model - GlobeNewsWire